Pulse Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
Pulse Biosciences, Inc. (PLSE) filed a Current Report on Form 8-K dated February 18, 2026, reporting events occurring on February 18 and February 19, 2026. The company is incorporated in Delaware and trades on The Nasdaq Stock Market.
Key Financial Metrics and Agreements
This filing does not contain financial performance data such as revenue, profit, cash flow, or margins. The primary financial event reported is the entry into a new equity distribution agreement.
- New Offering Capacity: The Company may offer and sell shares of common stock with an aggregate offering price of up to $59,976,196.
- Sales Agent: TD Securities (USA) LLC ("TD Cowen") was appointed as the sales agent.
- Commission: TD Cowen will receive compensation at a commission rate of up to 3.0% of the gross sales price of shares sold.
- Sale Method: Shares may be sold via "at-the-market" offerings, block trades, or negotiated transactions at prevailing market prices.
Material Changes
The Company terminated its prior equity distribution agreement dated July 15, 2024, effective February 18, 2026. Under the terminated agreement, shares with an aggregate offering price of up to $59,976,196 remained unsold. Immediately following termination, the Company entered into the new Sales Agreement with TD Cowen for the same aggregate offering amount.
Outlook, Risks, and Management Commentary
The Company is not obligated to sell any shares under the new Sales Agreement and retains the right to suspend solicitations and offers at any time. The issuance of shares will be made pursuant to effective registration statements on Form S-3 filed in 2024. The filing includes a legal opinion from Baker & Hostetler LLP regarding the validity of the issuance.
Key Facts for Investor Verification
- Verify the current share price to assess the potential dilution impact of selling up to $59,976,196 in shares.
- Confirm the total number of shares outstanding to calculate the percentage increase in share count if the full offering is utilized.
- Review the Company's cash position and burn rate to understand the necessity of this capital raise.
- Monitor future filings for actual sales volumes and proceeds generated under the new agreement.